Stock 300942 SHENZHEN BIOEASY BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shenzhen Bioeasy Biotechnology Co., Ltd.

Equities

300942

CNE100004C78

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
7.31 CNY -1.22% Intraday chart for Shenzhen Bioeasy Biotechnology Co., Ltd. -5.80% -37.47%
Apr. 25 Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 25 Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 11,569 6,871 4,686
Enterprise Value (EV) 1 10,928 6,561 4,450
P/E ratio 48.1 x 81.6 x -25.4 x
Yield 0.86% 0.12% -
Capitalization / Revenue 19.4 x 10 x 18.4 x
EV / Revenue 18.3 x 9.55 x 17.5 x
EV / EBITDA 42.5 x 74.9 x -44.7 x
EV / FCF 108 x -117 x -46.8 x
FCF Yield 0.93% -0.86% -2.14%
Price to Book 12.2 x 7.12 x 5.52 x
Nbr of stocks (in thousands) 400,860 400,860 400,860
Reference price 2 28.86 17.14 11.69
Announcement Date 4/26/22 4/25/23 4/25/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 204.9 239.2 258.5 597.5 686.9 254.1
EBITDA 1 73.13 82.73 71.9 257 87.58 -99.51
EBIT 1 68.65 77.99 66.47 248.1 76.28 -115.2
Operating Margin 33.5% 32.61% 25.72% 41.52% 11.1% -45.33%
Earnings before Tax (EBT) 1 84.68 106 73.94 268 94.89 -177.8
Net income 1 73.94 92.31 65.45 236.5 82.97 -184.9
Net margin 36.08% 38.59% 25.32% 39.58% 12.08% -72.77%
EPS 2 1.420 0.2600 0.1800 0.6000 0.2100 -0.4600
Free Cash Flow 1 24.97 8.168 -44.07 101.2 -56.19 -95.06
FCF margin 12.18% 3.42% -17.05% 16.93% -8.18% -37.41%
FCF Conversion (EBITDA) 34.14% 9.87% - 39.36% - -
FCF Conversion (Net income) 33.77% 8.85% - 42.77% - -
Dividend per Share - - 0.0450 0.2490 0.0212 -
Announcement Date 6/28/19 7/1/20 4/28/21 4/26/22 4/25/23 4/25/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 189 442 379 641 310 236
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 25 8.17 -44.1 101 -56.2 -95.1
ROE (net income / shareholders' equity) 43.8% 24.6% 12.2% 31.6% 8.65% -20.4%
ROA (Net income/ Total Assets) 18.2% 10.6% 6.53% 17.2% 3.92% -5.46%
Assets 1 405.5 867.8 1,002 1,377 2,119 3,389
Book Value Per Share 2 4.280 1.470 1.530 2.360 2.410 2.120
Cash Flow per Share 2 3.640 1.230 1.050 0.8500 0.6200 1.200
Capex 1 10.5 26.3 82.8 79.5 177 129
Capex / Sales 5.14% 10.99% 32.05% 13.31% 25.75% 50.63%
Announcement Date 6/28/19 7/1/20 4/28/21 4/26/22 4/25/23 4/25/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
SHENZHEN BIOEASY BIOTECHNOLOGY CO., LTD. Stock Shenzhen Bioeasy Biotechnology Co., Ltd.
-37.47% 405M
BIOMÉRIEUX Stock bioMérieux
-4.92% 12.27B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-5.82% 7.99B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+5.43% 5.69B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+26.16% 5.42B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-9.58% 4.13B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-59.63% 2.7B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+8.44% 2.6B
VITROLIFE AB Stock Vitrolife AB
-3.70% 2.38B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+21.00% 2.1B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 300942 Stock
  4. Financials Shenzhen Bioeasy Biotechnology Co., Ltd.